Loading...
XHKG
1530
Market cap3.74bUSD
Apr 11, Last price  
12.40HKD
1D
5.26%
1Q
117.93%
Jan 2017
64.24%
IPO
28.23%
Name

3SBio Inc

Chart & Performance

D1W1MN
P/E
17.59
P/S
3.49
EPS
0.66
Div Yield, %
2.02%
Shrs. gr., 5y
-2.38%
Rev. gr., 5y
11.26%
Revenues
9.11b
+16.53%
0000000656,145,000875,396,0001,130,854,0001,673,126,0002,797,289,0003,734,334,0004,583,869,0005,318,091,0005,587,636,0006,382,009,0006,859,433,0007,815,938,0009,107,978,000
Net income
2.09b
+34.93%
0000000101,666,00095,892,000291,728,000526,280,000712,564,000935,389,0001,277,167,000973,717,000835,791,0001,651,247,0001,915,727,0001,549,239,0002,090,320,000
CFO
0k
-100.00%
144,449,000217,254,000386,589,000455,274,0001,004,324,0001,074,098,0001,150,251,0001,887,384,0001,344,561,0001,578,345,0002,180,278,0002,082,857,0000
Dividend
Jul 21, 20250.25 HKD/sh
Earnings
Jun 24, 2025

Profile

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
URL
https://www.3sbio.com/
IPO date
Jun 11, 2015
Employees
5,311
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,107,978
16.53%
7,815,938
13.94%
6,859,433
7.48%
Cost of revenue
6,459,429
5,456,142
4,845,216
Unusual Expense (Income)
NOPBT
2,648,549
2,359,796
2,014,217
NOPBT Margin
29.08%
30.19%
29.36%
Operating Taxes
500,536
392,167
366,016
Tax Rate
18.90%
16.62%
18.17%
NOPAT
2,148,013
1,967,629
1,648,201
Net income
2,090,320
34.93%
1,549,239
-19.13%
1,915,727
16.02%
Dividends
(224,883)
(417,140)
Dividend yield
1.22%
1.90%
Proceeds from repurchase of equity
337
(475,511)
BB yield
0.00%
2.16%
Debt
Debt current
3,485,117
2,121,338
375,493
Long-term debt
116,217
2,754,053
4,132,891
Deferred revenue
416,914
Other long-term liabilities
643,598
667,313
4,474
Net debt
(5,655,484)
(946,746)
978,918
Cash flow
Cash from operating activities
2,082,857
2,180,278
CAPEX
(624,717)
(973,734)
Cash from investing activities
(1,345,355)
(3,721,985)
Cash from financing activities
(352,976)
714,912
FCF
2,480,089
6,117,889
(1,559,117)
Balance
Cash
6,318,330
5,992,081
7,010,514
Long term investments
2,938,488
(169,944)
(3,481,048)
Excess cash
8,801,419
5,431,340
3,186,494
Stockholders' equity
15,542,630
11,654,654
11,610,479
Invested Capital
13,432,914
16,587,416
16,946,940
ROIC
14.31%
11.74%
10.74%
ROCE
11.91%
10.72%
9.87%
EV
Common stock shares outstanding
2,466,608
2,441,666
2,648,209
Price
6.08
-19.15%
7.52
-9.40%
8.30
27.69%
Market cap
14,996,975
-18.32%
18,361,331
-16.46%
21,980,133
22.07%
EV
11,941,563
19,894,414
25,396,827
EBITDA
2,648,549
2,694,644
2,396,262
EV/EBITDA
4.51
7.38
10.60
Interest
212,296
101,053
Interest/NOPBT
9.00%
5.02%